Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
| Market Capitalization | $167.6452 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.191 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.18 |
| EBITDA | -59,884.852 |
| Profit Margin | 0 |
| Operating Margin TTM | -1283.9714 |
| Return on Assets TTM | -0.6373 |
| Return on Equity TTM | -1.0816 |
| Revenue TTM | 46.76 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2014-06-30 | 0 | 0 | 0 | 231.438 |
| 2015-06-30 | 7.33 | 0 | 0 | 1,572.636 |
| 2016-06-30 | 1,394.16 | 0 | 1,290.593 | 4,321.121 |
| 2017-06-30 | 1,848.92 | 0 | 1,823.303 | 6,140.997 |
| 2018-06-30 | 2,736.4 | 0 | 2,682.501 | 8,935.104 |
| 2019-06-30 | 3,245.63 | 2,983.918 | 11,952.536 | |
| 2020-06-30 | 4,695.49 | 17,173.331 | ||
| 2021-06-30 | 20.55 | 99.138 | -78.588 | 43,312.03 |
| 2022-06-30 | 79.224 | 143.751 | -64.527 | 47,925.999 |
| 2023-06-30 | 46.76 | 18.827 | 27.933 | 60,066.44 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2014-06-30 | 7.772 | 216.8 | 368.665 | 195.783 | 0.001 | |
| 2015-06-30 | 7,501.293 | 15,041.584 | 577.325 | 171.783 | 15,181.979 | |
| 2016-06-30 | 2,998.352 | 12,346.803 | 1,116.684 | 36.589 | 15,071.813 | |
| 2017-06-30 | 2,590.812 | 14,345.209 | 955.289 | 36.589 | 21,057.052 | |
| 2018-06-30 | 2,445.63 | 15,191.166 | 1,327.097 | 36.589 | 26,632.585 | |
| 2019-06-30 | 72,336.173 | 85,510.901 | 2,704.583 | 6,500 | 109,468.292 | |
| 2020-06-30 | 103,922.241 | 112,363.632 | 4,181.913 | 124.731 | 145,865.076 | |
| 2021-06-30 | 71,034.983 | 84,792.18 | 6,518.894 | 134.616 | 146,989.484 | |
| 2022-06-30 | 39,674.413 | 50,688.869 | 8,376.258 | 147.758 | 147,194.772 | |
| 2023-06-30 | 56,333.085 | 67,069.644 | 13,391.873 | 104.971 | 209,833.883 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2014-06-30 | -231.438 | -617.724 | 46.632 | |||
| 2015-06-30 | -1,565.305 | -1,203.28 | 117.09 | 124.857 | ||
| 2016-06-30 | -2,924.425 | -3,588.078 | 2,873.495 | 124.857 | 2,998.352 | 0 |
| 2017-06-30 | -4,275.446 | -4,470.404 | -407.54 | 2,998.352 | 2,590.812 | 0 |
| 2018-06-30 | -6,190.232 | -6,013.461 | -145.182 | 2,590.812 | 2,445.63 | |
| 2019-06-30 | -26,231.536 | -6,365.095 | 69,890.543 | 2,445.63 | 72,336.173 | |
| 2020-06-30 | -12,333.055 | -10,090.057 | 31,586.068 | 72,336.173 | 103,922.241 | |
| 2021-06-30 | -34,334.906 | -34,929.485 | -32,887.258 | 103,922.241 | 71,034.983 | |
| 2022-06-30 | -39,278.217 | -39,217.248 | -31,360.57 | 71,034.983 | 39,674.413 | |
| 2023-06-30 | -51,910.013 | -45,186.28 | 16,658.672 | 39,674.413 | 56,333.085 |